Ardena Capabilities Update November 2026: Bioavailability/ Solubility
Overcoming poor bioavailability in oral small molecule development requires selecting the right formulation technology early—without exhausting scarce active pharmaceutical ingredients (API). By pairing computational modeling with the Developability Classification System (DCS), formulation teams can evaluate up to six enabling technologies, such as hot melt extrusion (HME) and spray drying, starting with zero milligrams of API and progressing to micro-prototypes using just a few grams.
At Ardena’s Somerset, New Jersey facility, this data-driven screening connects directly to matched development and cGMP commercial equipment, on-site GLP bioanalysis, and a transatlantic manufacturing network. Whether managing potent compounds, controlled substances, or complex solubility profiles, aligning formulation science with scalable infrastructure reduces late-stage risk and accelerates paths to the clinic.
Watch the full session to explore how early, API-sparing formulation strategies and integrated bioanalysis streamline oral drug development from first batch to commercial supply.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.